Factores asociados a la muerte por COVID-19 en pacientes admitidos en un hospital público en Tacna, Perú
Miguel Hueda-Zavaleta, Cesar Copaja-Corzo, Fabrizzio Bardales-Silva, Rodrigo Flores-Palacios, Luis Barreto-Rocchetti, Vicente A Benites-Zapata
Revista Peruana de Medicina Experimental y Salud Pública, doi:10.17843/rpmesp.2021.382.7158
Objective: To describe the clinical, laboratory and treatment characteristics of COVID-19 patients and to determine the factors associated with mortality during hospital stay. Materials and Methods: Retrospective cohort study of adult COVID-19 inpatients. The clinical, laboratory and treatment data were obtained from the medical records of patients from the Hospital Nivel III Daniel Alcides Carrión in Tacna. For the survival analysis we used the Cox proportional hazards model, and we calculated crude and adjusted hazard ratios (HR) with 95% confidence intervals (95% CI). Results: We evaluated 351 patients; 74.1% of them were men. The most common comorbidities were obesity (31.6%), hypertension (27.1%) and diabetes mellitus (24.5%). The median time of hospitalization was 8 days (IQR: 4-15). From the total of patients, 32.9% died during follow-up. The multivariate analysis showed an increased risk of dying associated with the following: age ≥65 years, HR = 3.55 (95% CI: 1.70-7.40); increase in lactate dehydrogenase >720 U/L, HR = 2.08 (95% CI: 1.34-3.22); and oxygen saturation less than 90%, mainly when it was less than 80%, HR = 4.07 (95% CI: 2.10-7.88). In addition, the use of colchicine during treatment showed a protective effect, HR = 0.46 (95% CI: 0.23-0.91). Conclusions: Risk factors for mortality due to COVID-19 included being older than 65 years, having oxygen saturation less than 90%, and elevated lactate dehydrogenase >720 U/L; colchicine treatment could improve the prognosis of patients.
Author contributions: MHZ and CCC conceived the research idea, wrote the article, and carried out the data analysis and interpretation. FBS, RFP and LBR participated in data collection and wrote the article. VABZ participated in data analysis and interpretation, statistical and technical advice, and critical revision of the article. All authors approved the final version of the manuscript.
Conflict of interest: The authors deny any conflict of interest.
References
Abdullahi, Emeribe, Mustapha, Fasogbon, Ofor et al., Exploring the genetics, ecology of SARS-COV-2 and climatic factors as possible control strategies against COVID-19, Ahead Of Print1
Benites-Goñi, Vargas-Carrillo, Peña-Monge, Taype-Rondan, Arróspinde-Mormontoy et al., Características clínicas, manejo y mortalidad de pacientes hospitalizados con CO-VID-19 en un hospital de referencia en Lima, Perú
Davidson, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA,
doi:10.1001/jama.2020.6775Deftereos, Siasos, Giannopoulos, Vrachatis, Angelidis et al., The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design, Hellenic J Cardiol,
doi:10.1016/j.hjc.2020.03.002Diaz, Riviello, Papali, Adhikari, Ferreira, Global Critical Care: Moving Forward in Resource-Limited Settings, Ann Glob Health,
doi:10.5334/aogh.2413Díaz-Vélez, Urrunaga-Pastor, Romero-Cerdán, Peña-Sánchez, Fernández et al., Risk factors for mortality in hospitalized patients with COVID-19 from three hospitals in Peru: a retrospective cohort study [version 1; peer review: awaiting peer review, F1000Research,
doi:10.12688/f1000research.51474.1Gianella, Iguiñiz-Romero, Romero, Good Health Indicators are Not Enough: Lessons from COVID-19 in Peru, Health Hum Rights
Horby, Pessoa-Amorim, Peto, Brightling, Sarkar et al., Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Investigators, Gordon, Mouncey, Al-Beidh, Rowan et al., Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2100433Mcginn, None
Mejía, Medina, Cornejo, Morello, Vásquez et al., Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru, PLoS One,
doi:10.1371/journal.pone.0244171Richardson, Hirsch, Narasimhan, Crawford, None
Rodríguez-Zúñiga, Quintana-Aquehua, Díaz-Lajo, Charaja-Coata, Becerra-Bonilla et al., Factores de riesgo asociados a mortalidad en pacientes adultos con neumonía por SARS-CoV-2 en un hospital público de Lima, Perú, Acta Med Peru,
doi:10.35663/amp.2020.374.1676Salama, Mohan, Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply, N Engl J Med,
doi:10.1056/NEJMc2100217Salomaa, Bouffler, Atkinson, Cardis, Hamada, Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?, Int J Radiat Biol,
doi:10.1080/09553002.2020.1786609Sandhu, Tieng, Chilimuri, Franchin, A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection, Can J Infect Dis Med Microbiol,
doi:10.1155/2020/8865954Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2028836Suleyman, Fadel, Malette, Hammond, Abdulla et al., Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit, JAMA Netw Open,
doi:10.1001/jama-networkopen.2020.12270Vena, Giacobbe, Biagio, Mikulska, Taramasso et al., GECOVID study group. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy, Clin Microbiol Infect,
doi:10.1016/j.cmi.2020.07.049Vrachatis, Giannopoulos, Giotaki, Raisakis, Kossyvakis et al., Impact of colchicine on mortality in patients with COVID-19. A meta-analysis, Hellenic J Cardiol,
doi:10.1016/j.hjc.2020.11.012
